JP2017519764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519764A5 JP2017519764A5 JP2016573762A JP2016573762A JP2017519764A5 JP 2017519764 A5 JP2017519764 A5 JP 2017519764A5 JP 2016573762 A JP2016573762 A JP 2016573762A JP 2016573762 A JP2016573762 A JP 2016573762A JP 2017519764 A5 JP2017519764 A5 JP 2017519764A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 72
- 239000000203 mixture Substances 0.000 claims 29
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 24
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 24
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 24
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 24
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 11
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 11
- 208000020832 chronic kidney disease Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 4
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 4
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 4
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 4
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 4
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 4
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 4
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 230000008085 renal dysfunction Effects 0.000 claims 4
- 206010062237 Renal impairment Diseases 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 230000003907 kidney function Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 102000008857 Ferritin Human genes 0.000 claims 1
- 108050000784 Ferritin Proteins 0.000 claims 1
- 238000008416 Ferritin Methods 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000036325 urinary excretion Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015242P | 2014-06-20 | 2014-06-20 | |
| US62/015,242 | 2014-06-20 | ||
| PCT/US2015/036794 WO2015196145A1 (en) | 2014-06-20 | 2015-06-19 | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519764A JP2017519764A (ja) | 2017-07-20 |
| JP2017519764A5 true JP2017519764A5 (enExample) | 2018-07-26 |
| JP6768527B2 JP6768527B2 (ja) | 2020-10-14 |
Family
ID=53724443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573762A Active JP6768527B2 (ja) | 2014-06-20 | 2015-06-19 | Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170137506A1 (enExample) |
| EP (1) | EP3157953B1 (enExample) |
| JP (1) | JP6768527B2 (enExample) |
| AU (2) | AU2015276800B2 (enExample) |
| CA (1) | CA2952032C (enExample) |
| EA (1) | EA201790051A1 (enExample) |
| MX (1) | MX2016016826A (enExample) |
| WO (1) | WO2015196145A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100689A1 (en) | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| WO2017109706A1 (en) * | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EP4006049A1 (en) * | 2016-01-29 | 2022-06-01 | Washington University | Gdf15 in glaucoma and methods of use thereof |
| JP7138567B2 (ja) | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5733254A (en) | 1987-10-15 | 1998-03-31 | Cypress Bioscience, Inc. | Method for treating patients suffering from immune thrombocytopenic purpura |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| AU2002257420A1 (en) | 2001-05-01 | 2002-11-11 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| ES2555956T3 (es) * | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| WO2009021293A1 (en) | 2007-08-16 | 2009-02-19 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| CN101951921A (zh) | 2007-09-17 | 2011-01-19 | 比奥尼里斯有限责任公司 | 用于治疗恶病质的方法和手段 |
| JP2011502106A (ja) * | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法 |
| WO2010048670A1 (en) * | 2008-10-31 | 2010-05-06 | St Vincent's Hospital Sydney Limited | Method of prognosis in chronic kidney disease |
| EP3590537A1 (en) * | 2012-09-26 | 2020-01-08 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| WO2014100689A1 (en) * | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
-
2015
- 2015-06-19 EP EP15742143.9A patent/EP3157953B1/en active Active
- 2015-06-19 US US15/320,101 patent/US20170137506A1/en not_active Abandoned
- 2015-06-19 WO PCT/US2015/036794 patent/WO2015196145A1/en not_active Ceased
- 2015-06-19 MX MX2016016826A patent/MX2016016826A/es unknown
- 2015-06-19 EA EA201790051A patent/EA201790051A1/ru unknown
- 2015-06-19 AU AU2015276800A patent/AU2015276800B2/en active Active
- 2015-06-19 JP JP2016573762A patent/JP6768527B2/ja active Active
- 2015-06-19 CA CA2952032A patent/CA2952032C/en active Active
-
2018
- 2018-11-02 US US16/179,166 patent/US11897948B2/en active Active
-
2021
- 2021-05-31 AU AU2021203523A patent/AU2021203523A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519764A5 (enExample) | ||
| JP2009530423A5 (enExample) | ||
| NZ744036A (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| JP2011515073A5 (enExample) | ||
| JP2007520494A5 (enExample) | ||
| JP2010507594A5 (enExample) | ||
| WO2008150946A8 (en) | HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF | |
| SI2327421T1 (sl) | Stabilizirane tekoče formulacije protitelesa proti-RSV | |
| JP2021191267A5 (enExample) | ||
| JP2017519765A5 (enExample) | ||
| TN2010000201A1 (en) | Anti-hepcidin antibodies and uses thereof | |
| JP2023078174A5 (enExample) | ||
| JP2013127002A5 (enExample) | ||
| JP2009539348A5 (enExample) | ||
| EA201200795A1 (ru) | Связывающие элементы для пептида с5а с высоким ингибирующим действием | |
| JP2020176155A5 (enExample) | ||
| MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
| WO2009117030A3 (en) | Improved compositions for the prevention and treatment of smallpox | |
| JP2019533695A5 (enExample) | ||
| JP2009508822A5 (enExample) | ||
| AU2018260858A1 (en) | Perm selective membrane for treating vascular calcification in chronic hemodialysis patients | |
| JP2018526443A5 (enExample) | ||
| WO2011012609A3 (en) | Anti - tgf - beta receptor type ii single domain antibodies | |
| WO2007019153A3 (en) | Methods for treating hypertension | |
| HRP20231469T1 (hr) | Poboljšani protokol za liječenje lupus nefritisa |